Grifols ‘continues global expansion’

Grifols has continued its global expansion with the acquisition of a Swiss and Australian group.

The company explains a transaction worth 25 million euros (22.42 million pounds) was undertaken through a capital increase in the body.

Grifols now owns 49 per cent of the capital stock in the group, as well as gaining full control.

A holding company with three differentiated areas of activity will serve as a medium for the transaction.

Ramon Riera, commercial vice-president of Grifols, states: "With the establishment of a presence in the US – and after having significantly enhanced the production of biological products – the company is now focusing on increasing its market share in the countries of Latin America.

Asia – specifically China – is also a target for the company, he added, stating the firm needs to wait until it has a sufficient market share in the USA and for production to be increased before it can move forwards.

In recent days, Grifols announced registration has officially opened for participation in the 2009 Martin Villar Haemostasis Awards.